B-Cell Malignant Neoplasm — Trials

B-Cell Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

7,466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,083
Recruiting: 1,077
Ph III recruiting: 121
Growth YoY: +2.3%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,167)

clinicaltrialsPublishedShowing 301–350 of 975 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01618136	An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors	completed	Phase 1 / Phase 2	41	Eisai LimitedINDUSTRY	1	Jun 18, 2023	clinicaltrials
NCT03003546	Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial	completed	Phase 1	9	Mayo ClinicOTHER